Diabetes drug may shield kidneys from chemo damage
NCT ID NCT07018622
First seen Mar 13, 2026 · Last updated Apr 29, 2026 · Updated 5 times
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney injury in people receiving platinum-based chemotherapy for solid tumors. About 46 participants will receive either dapagliflozin or a placebo, and researchers will measure kidney damage markers in urine. The goal is to find a safe way to protect kidneys without interfering with cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
RECRUITINGMéxico, Tlalpan, 14080, Mexico
Conditions
Explore the condition pages connected to this study.